CVRx (CVRX)

• Market cap: $388M
• 1 day: -4.94%
• 5 days: -8.37%
• 1 month: 26.12%
• 3 months: 21.80%
• 6 months: 86.90%
• Year to date: 17.67%
• 1 year: -36.39%
• 5 years: -42.93%
• 10 years: -42.93%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Employees: 200

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

119% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 16

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

54% more call options, than puts

Call options by funds: $653K | Put options by funds: $425K

16% more funds holding

Funds holding: 73 [Q2] → 85 (+12) [Q3]

2.86% more ownership

Funds ownership: 61.99% [Q2] → 64.85% (+2.86%) [Q3]

23% less capital invested

Capital invested by funds: $161M [Q2] → $124M (-$36.4M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $22 38% upside
• Avg. target: $22 38% upside
• High target: $22 38% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Craig-Hallum Alexander Nowak 73% 1-year accuracy 11 / 15 met price target	38% upside $22	Buy Maintained	17 Jan 2025
Canaccord Genuity William Plovanic 78% 1-year accuracy 36 / 46 met price target	38% upside $22	Buy Maintained	9 Dec 2024